Download presentation
1 -

From COVID-19 to COVI-Flu: A Burgeoning Pandemic


Page 9 Yan Leyfman 1 , Timothy K. Erick 1 , Pushpa Sharma 1,2 1 WACEM-ACAIM Joint Global COVID-19 Taskforce— Immunology Division, USA 2 Department of Anaesthesiology, Uniformed Services Universit

oryan's Recent Documents

ANEXTREMAL PROBLEM IN GRAPH THEORYPErdsand E HoworkaThe distance dGuvb
ANEXTREMAL PROBLEM IN GRAPH THEORYPErdsand E HoworkaThe distance dGuvb

thenIuvVEuvnS011x0000rl1/rtptycntTheroofisbinductiononrTheassertionclearlyholdsforr 1Let k 2andsupposethattheassertionholdsforr k-1 Let G VEbeagraph satisfyingwith r kLet S0be a maximal subset of S

published 1K
31 3029282726253124262322 2321 242019 18232526192417 2321 252316302316
31 3029282726253124262322 2321 242019 18232526192417 2321 252316302316

Meet Ibrahim Yeku CCEP-IBarrister Solicitor Solola AkpanaOld GRA Port Harcourt NigeriacorporatecomplianceorgCompliance EthicsPROFESSIONALThis article published in appears here with permission from

published 0K
6RPHHQJLQHVXVHGRQ7RUR3URGXFWVDUHZDUUDQWHGEWKHHQJLQHPDQXIDFWXUHU5HVLGHQ
6RPHHQJLQHVXVHGRQ7RUR3URGXFWVDUHZDUUDQWHGEWKHHQJLQHPDQXIDFWXUHU5HVLGHQ

XVWRPHUDUHHSDUWPHQW5/LYLVLRQ7RURDUUDQWRPSDQ/QGDOHYHQXH6RXWKORRPLQJWRQ017ROOIUHHDW86FXVWRPHUV7ROOIUHHDWDQDGLDQFXVWRPHUVWHPVDQGRQGLWLRQV1RWRYHUHG7KHUHLVQRRWKHUHSUHVVZDUUDQWHFHSWIRUVSHFLDOHPLVVLRQVVWHPFR

published 0K
Phillips R A McNaught C  Kennedy G 2010 Towards a generalised conceptu
Phillips R A McNaught C Kennedy G 2010 Towards a generalised conceptu

for example cognitive psychology or neuroscience although these disciplines may enrich the framework once it has been refined at a philosophical level There can be many interpretations of the word lea

published 0K
Roadmap to Success
Roadmap to Success

Achieving a Net-Zero Carbon Futureby 2050A Strategic Plan for the Liquid Heating Fuel Industry to Accelerate and Achieve Net Carbon ReductionsAuthor KearneytheNational Energy FuelsInstituteNEFIPublis

published 0K
Building the Business Case for SustainabilityROSI 101 Workshop
Building the Business Case for SustainabilityROSI 101 Workshop

OBJECTIVEShow how ROSI can help build a more complete business case for investing in sustainability by capturing all benefitsAGENDAROSI FundamentalsROSI In Action Applied Examples ROSI Implementation

published 0K
Towards the Use of Controlled Natural Languages in Hazard Analysis and
Towards the Use of Controlled Natural Languages in Hazard Analysis and

Towards the Use of Controlled Natural Languages in Hazard Analysis and Risk AssessmentPaul Chomicz 31052017Introduction ISO 26262x0000x0000Hazard Analysisx0000x0000Risk AssessmentInitiation of Safety

published 0K
Date MarkingSEVEN DAY LIMIT FOR READYTOEAT FOODWhat to date markDate m
Date MarkingSEVEN DAY LIMIT FOR READYTOEAT FOODWhat to date markDate m

x0000x0000DATE MARKINGx0000x00002 Preserved fish products such as pickled herring and dried or salted cod and certain other acidified fish productsShelfstable dry fermented sausages such as pepperoni

published 0K
Download Section

Download - The PPT/PDF document "" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.






Document on Subject : "From COVID-19 to COVI-Flu: A Burgeoning Pandemic"— Transcript:

1 Page 9 From COVID-19 to COVI-Flu: A Burg
Page 9 From COVID-19 to COVI-Flu: A Burgeoning Pandemic Yan Leyfman 1 , Timothy K. Erick 1 , Pushpa Sharma 1,2 1 WACEM-ACAIM Joint Global COVID-19 Taskforce— Immunology Division, USA 2 Department of Anaesthesiology, Uniformed Services University of the Health Sciences, Bethesda, MD, USA Citation: Yan Leyfman; From COVID-19 to COVI-Flu: A Burgeoning Pandemic; COVID Vaccines 2020 ; August 31, 2020 | Paris, France Webinar on COVID-19 Vaccination | August 31, 2020 | Paris, France Abstract: Coronavirus disease 2019 (COVID-19), a respiratory ill - ness caused by the novel betacoronavirus SARS-CoV-2, has rapidly caused a global pandemic. This viral infec - tion has broad symptomatic presentations, ranging from asymptomatic to fatal. Studies have demonstrated that patients with severe symptoms and elevated pro-inflam - matory (IL-1β, IL-6, IFN-, and TNF-) and lower anti-in - flammatory cytokine levels (IL-10) tend to possess a poor prognosis. Based on the available evidence, we proposed a mechanism by which SARS-CoV-2 infection causes systemic organ damage through IL-6-mediated inflam - mation. Elevated IL-6 fuels a cytokine release syndrome and hypoxia, resulting in vast systemic injury, multi-or - gan damage, and eventually organ failure. Additionally, we propose a potential synergism between influenza virus and SARS-CoV-2, which we termed “COVI-Flu.” Under our model, simultaneous infection with both viruses will cause a further increase in IL-6 production, which will yield more widespread systemic inflammation and injury than infection with either virus alone. Current - ly, there are no available safe and effective therapeutic interventions against SARS-CoV-2 or COVI-Flu. Based on the similarities between the disease mechanisms of SARS-CoV-2 and influenza virus, we proposed the idea of a combination therapy that can control the systemic inflammation induced by both viruses. One promising approach is a cellular therapy that has yielded promising preliminary efficacy in COVID-19 patients. Looking for - ward, we see combinational therapies being used that can better thwart the virus’s heterogeneity and mutational adaptations. In anticipation of the impending COVI-Flu pandemic Biography: Yan Leyfman has contributed to the development of sev - eral anti-cancer therapies that have recently entered clin - ical trials and his successes have been recognized by such prestigious organizations as the Barry M. Goldwater Re - search Foundation, Sigma Xi, New York Times, USA To - day, National Society of Collegiate Scholars, and Harvard Medical School. He has been recognized as one of the top medical student researchers in oncology nationally by the American Society of Hematology and American Society of Clinical Oncology and locally by the Pennsylvania Society of Oncology & Hematology and the American College of Physicians. During the COVID-19 pandemic, he was re - cruited to join the Global COVID-19 Taskforce to serve as a Special Advisor for Immunology, Oncology and Cellular Therapeutics and was made Director of the Immunology Group, which produced a cohesive mechanism of action for SARS-CoV-2, a new prognostic assay to predict patient outcomes, and the first synergistic paradigm between the flu and SARS-CoV-2, termed “COVI-Flu” along with therapeutic interventions for both. Within days of publi - cation ahead of print as the upcoming cover article in the journal, Shock, this manuscript received over 32 million views and was amongst the top five COVID-19 articles worldwide according to QxMD. Publication of speakers: 1. de Brito, R. C., N. Lucena-Silva, L. C. Torres, C. F. Luna, J. B. Correia, and G. A. da Silva. 2016. The balance between the serum levels of IL-6 and IL-10 cytokines discriminates mild and severe acute pneu - monia. BMC Pulm Med 16: 170. Journal of Vaccines and Vaccination Abstract J Vaccines and Vaccination 2020 Volume and Issue: S(3)